Universität zu Köln

Gerhard-Hartmann, Elena ORCID: 0000-0003-2134-2774, Goergen, Helen, Broeckelmann, Paul J., Mottok, Anja, Steinmueller, Tabea ORCID: 0000-0001-7099-1223, Grund, Johanna, Zamo, Alberto, Ben-Neriah, Susana, Sasse, Stephanie, Borchmann, Sven ORCID: 0000-0001-6662-6864, Fuchs, Michael, Borchmann, Peter, Reinke, Sarah, Engert, Andreas, Veldman, Johanna ORCID: 0000-0003-4253-0870, Diepstra, Arjan ORCID: 0000-0001-9239-1050, Klapper, Wolfram and Rosenwald, Andreas (2022). 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial. Br. J. Haematol., 196 (1). S. 116 - 127. HOBOKEN: WILEY. ISSN 1365-2141

Full text not available from this repository.

Abstract

High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed-Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the German Hodgkin Study Group (GHSG) NIVAHL trial (ClinicalTrials.gov Identifier: NCT03004833). All evaluated specimens showed 9p24.1 CNA in HRSC to some extent, but with high intratumoral heterogeneity and an overall smaller range of alterations than reported in advanced-stage or r/r cHL. All but two cases (97%) showed PD-L1 expression by the tumour cells in variable amounts. While MHC-I was rarely expressed in >50% of HRSC, MHC-II expression in >50% of HRSC was found more frequently. No obvious impact of 9p24.1 CNA or PD-L1 and MHC-I/II expression on early response to the highly effective anti-PD-1-based NIVAHL first-line treatment was observed. Further studies evaluating an expanded panel of potential biomarkers are needed to optimally stratify anti-PD-1 first-line cHL treatment.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Gerhard-Hartmann, Elena UNSPECIFIED orcid.org/0000-0003-2134-2774 UNSPECIFIED Goergen, Helen UNSPECIFIED UNSPECIFIED UNSPECIFIED Broeckelmann, Paul J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Mottok, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Steinmueller, Tabea UNSPECIFIED orcid.org/0000-0001-7099-1223 UNSPECIFIED Grund, Johanna UNSPECIFIED UNSPECIFIED UNSPECIFIED Zamo, Alberto UNSPECIFIED UNSPECIFIED UNSPECIFIED Ben-Neriah, Susana UNSPECIFIED UNSPECIFIED UNSPECIFIED Sasse, Stephanie UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Sven UNSPECIFIED orcid.org/0000-0001-6662-6864 UNSPECIFIED Fuchs, Michael UNSPECIFIED UNSPECIFIED UNSPECIFIED Borchmann, Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED Reinke, Sarah UNSPECIFIED UNSPECIFIED UNSPECIFIED Engert, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Veldman, Johanna UNSPECIFIED orcid.org/0000-0003-4253-0870 UNSPECIFIED Diepstra, Arjan UNSPECIFIED orcid.org/0000-0001-9239-1050 UNSPECIFIED Klapper, Wolfram UNSPECIFIED UNSPECIFIED UNSPECIFIED Rosenwald, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-599724
DOI:	10.1111/bjh.17793
Journal or Publication Title:	Br. J. Haematol.
Volume:	196
Number:	1
Page Range:	S. 116 - 127
Date:	2022
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1365-2141
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language SINGLE-ARM; PD-L1 IMMUNOHISTOCHEMISTRY; BRENTUXIMAB VEDOTIN; DIAGNOSTIC-TOOL; NIVOLUMAB; BLOCKADE; TRANSPLANTATION; MULTICOHORT; MULTICENTER; FAILURE Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59972